SLC5A2 and myocardial infarction: Due to the increasing evidence in various disease states and the suggested mechanisms of action, it seems reasonable to explore the potential of SGLT2 inhibition in improving outcomes for patients with acute myocardial infarction if administered promptly after the presentation.